Sight Sciences (NASDAQ:SGHT) EVP Brenton Taylor Sells 2,869 Shares
by Mitch Edgeman · The Markets DailySight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) EVP Brenton Taylor sold 2,869 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $3.70, for a total transaction of $10,615.30. Following the completion of the transaction, the executive vice president directly owned 267,807 shares in the company, valued at approximately $990,885.90. This represents a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Brenton Taylor also recently made the following trade(s):
- On Tuesday, January 6th, Brenton Taylor sold 619 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total transaction of $4,630.12.
Sight Sciences Stock Performance
Shares of Sight Sciences stock remained flat at $3.52 on Friday. 236,639 shares of the stock were exchanged, compared to its average volume of 413,049. The company has a debt-to-equity ratio of 0.63, a quick ratio of 9.52 and a current ratio of 10.22. The stock has a market cap of $190.10 million, a price-to-earnings ratio of -4.69 and a beta of 2.50. The firm’s 50 day simple moving average is $4.87 and its 200 day simple moving average is $5.73. Sight Sciences, Inc. has a 12 month low of $2.03 and a 12 month high of $9.24.
Sight Sciences (NASDAQ:SGHT – Get Free Report) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.07. Sight Sciences had a negative net margin of 49.67% and a negative return on equity of 55.72%. The business had revenue of $20.39 million for the quarter, compared to analysts’ expectations of $20.35 million. On average, equities research analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
SGHT has been the subject of a number of research analyst reports. Piper Sandler set a $9.00 price target on Sight Sciences in a report on Monday, January 5th. UBS Group reduced their price objective on Sight Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. Citigroup decreased their target price on Sight Sciences from $9.10 to $6.50 and set a “neutral” rating on the stock in a research report on Friday, March 6th. William Blair reissued an “outperform” rating on shares of Sight Sciences in a research note on Thursday, March 5th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sight Sciences in a report on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.31.
Read Our Latest Research Report on SGHT
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Americana Partners LLC lifted its stake in shares of Sight Sciences by 42.4% in the 3rd quarter. Americana Partners LLC now owns 1,229,819 shares of the company’s stock valued at $4,231,000 after acquiring an additional 365,901 shares during the last quarter. B Group Inc. grew its position in Sight Sciences by 11.6% during the 2nd quarter. B Group Inc. now owns 930,000 shares of the company’s stock worth $3,841,000 after acquiring an additional 96,400 shares during the last quarter. Intech Investment Management LLC grew its position in Sight Sciences by 26.2% during the 2nd quarter. Intech Investment Management LLC now owns 25,366 shares of the company’s stock worth $105,000 after acquiring an additional 5,261 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in Sight Sciences in the 4th quarter worth about $96,000. Finally, O Shaughnessy Asset Management LLC acquired a new position in Sight Sciences in the 4th quarter worth about $81,000. 55.51% of the stock is currently owned by institutional investors and hedge funds.
Sight Sciences Company Profile
Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.
Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.